OncoNano to Present New Preclinical Data at AACR 2026 Highlighting Effective Tumor Delivery Enabled by ON-BOARD™ Platform OncoNano Medicine, Inc. a clinical-stage biotechnology company developing precision therapies using its proprietary nanotechnology platform, announced it will present new preclinical data at the…
Volastra Therapeutics Announces Biomarker and Combination Data around AACR 2026 Defining an Rb Pathway-Driven Pan-Cancer Development Strategy for KIF18A Inhibitors Volastra Therapeutics, a clinical-stage oncology company pioneering therapies targeting chromosomal instability (CIN), announced multiple scientific disclosures coinciding with the American…
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker’s continued commitment to advancing integrated,…
Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform Foundation Medicine, Inc., a global, patient-focused precision medicine company and an independent affiliate of Roche, announced it is set to expand its monitoring portfolio with…
Delve Detect Enables Neurologists to Treat CNS Infections When Conventional Testing Fails Delve Bio, a UCSF spin-out and pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, announced data underscoring the clinical impact of mNGS using Delve Detect to identify pathogens and…
Forlong Biotechnology Announced CMC Readiness to Initiate GMP Batch Production to Support Upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC) Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients…
NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225 NorthStar Medical Radioisotopes, LLC a leading radiopharmaceutical company, today announced that it received notice of the U.S. Food & Drug Administration’s (FDA) acceptance of its Type II Drug Master…
Litmys and Konovo Form Partnership to Revolutionize Drug Development Intelligence for Life Sciences Companies Litmys, a life sciences commercial strategy consulting firm, specializing in the development of commercial readiness analytics, and Konovo, a technology-first healthcare intelligence company that accelerates access to…
AMGTA Releases Independent Report on Additive Manufacturing’s Role in Resource-Efficient Manufacturing Systems Following its 2026 Annual Member Summit, AMGTA released Additive Manufacturing in Resource-Efficient Manufacturing Systems, an independent report establishing how additive manufacturing should be evaluated, communicated, and deployed across part,…
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis Organon a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced…
Horizon Quantum and AQT to Advance Real-World Quantum Applications with Strategic Hardware–Software Collaboration Horizon Quantum Computing Pte. Ltd., the wholly-owned subsidiary of Horizon Quantum Holdings Ltd.a pioneer of software infrastructure for quantum applications, and AQT (Alpine Quantum Technologies), a leading…
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced…